RxDoctor Payments Data

Jordan Stern, MD

Vascular Surgery · New York, NYNPI 1578871315

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (29.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Penumbra, Inc. at 35.3% of the total. Reporting peaked in 2022 at $36,982 and has fallen 77.7% since, to $8,244 in 2025. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$129,611in general payments, 2019–2025

Across 770 payments — averaging $168.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$46K
  • W. L. Gore & Associates, Inc.$25K
  • Medtronic$14K
  • Cook Medical LLC$11K
  • Viz.ai, Inc.$10K
  • Abbott$9K
  • plus $15K from 26 others
$27,698in research payments, 2019–2025

Across 20 payments — averaging $1384.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Penumbra, Inc.$27K
  • Bolton Medical Inc$1K

What the payments were for

  • Consulting fees$30,34523%
  • Speaking & faculty fees$31,81025%
  • Travel & lodging$29,20423%
  • Food & beverage$38,17829%
  • Education$350%
  • Entertainment$380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,611 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.

See all vascular surgery providers in New York

Medicare billing

Part B allowed, 2024
$60,352
Medicare patients
121
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate11$102

Paid to pharmacies, not to this prescriber.

Other vascular surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →